Dr Himani. Foams or creams that people can use in vagina or rectum during sex to prevent transmission Currently, there is no vaccine to prevent HIV. This.

Slides:

Advertisements

Similar presentations

HIV/AIDS The Epidemic in ANE and E&E So what do we do now? Paul De Lay Senior Advisor on HIV/AIDS Office of HIV/AIDS.

Advertisements

Turning the tide: Not without prisons! Promoting comprehensive national HIV responses.

What is up with Nonoxynol-9? Global Campaign for Microbicides

Towards Universal Access Recommendations for a Public Health Approach BASED ON WHO GUIDELINES Antiretroviral Drugs for Treating Pregnant Women and Preventing.

STDs Valerie Robinson D.O.. Prevention Abstinence Risk reduction Vaccines Male or female condoms Cervical diaphragm might protect against cervical GC,

Dr. Carol Odula (Obs./Gyn.) May 7 th 2013 Preparing for pre-exposure prophylaxis (PrEP) to prevent HIV infection.

Microbicides Envision a product that could save lives Your name here

State of the Field Exploring 2015’s Top Ten List for the HIV Prevention Research Field Manju Chatani, Stacey Hannah, Mitchell Warren Thursday, January.

Preparing for pre-exposure prophylaxis (PrEP) to prevent HIV infection James Wilton Project Coordinator Biomedical Science of HIV Prevention

Journal Club Alcohol, Other Drugs, and Health: Current Evidence July–August 2013.

HIV in Texas: The Ways Forward Ann Robbins Manager of HIV/STD Prevention and Care Department of State Health Services.

New Prevention Technologies Workshop Module 3: Overview of Prevention Research

What can we learn from diverse spectrum of HIV/SIV infections? Françoise BARRÉ-SINOUSSI Regulation of Retroviral Infections Unit Department of Virology.

Rectal Microbicides: The Basics Date, Location Your name, Your affiliation.

The 4 th Decade of the HIV Epidemic: Midwest Regional Response September 17, 2013 with Jim Pickett, AFC/IRMA The Bottom Line on Rectal and Vaginal Microbicide.

Jim Pickett, IRMA/AFC GMHC – January 23, 2013 The Bottom Line on Rectal Microbicide Research.

Microbicide Research: A Promising HIV/AIDS Prevention Strategy for Women Roberta Black, Ph.D. Division of AIDS, National Institute of Allergy and Infectious.

Introduction to HIV New Prevention Technologies (NPTs)

Microbicides: Who, what, where, when and how Rebekah Webb Global Campaign for Microbicides © Salam Dahbor,

Cindra Feuer and Marc-André LeBlanc HRCF, 21 April 2010 ARV-based Prevention.

Prior to exposure Point of transmission After infection Male and female condoms Antiretroviral therapy (mother-to- child) Post exposure prophylaxis (PEP)

Microbicides for HIV Prevention Pamina M. Gorbach, Epidemiology & Infectious Diseases UCLA.

SEXUALLY TRANSMITTED DISEASES

Sexually transmitted diseases. Increasing due to: n Increasing sexual activity n Multiple sexual partners n Use of birth control pills – Increases the.

Microbicides: Science, research, and overview of the field Dr Kamini Walia, Indian Council of Medical Research, New Delhi Bindiya Patel, Global Campaign.

HIV/AIDS VACCINE AWARENESS Vaccine 101 Jeremiah Brewer Health and Training Educator African – Americans Reach and Teach Health Ministry.

DEVELOPING DUAL COMPARTMENT MPTS THAT WORK UP FRONT AND FROM BEHIND José Fernández Romero Population Council September 9, 2015.

Katharine Kripke, Ph.D. Assistant Director, Vaccine Research Program, Division of AIDS, NIAID AIDS Vaccine 2011 Journalist Training Program September 11,

What sexually transmitted diseases can I get? © Robert J. Atkins, Ph.D.

Rectal Microbicides: New Hope for HIV and STD Prevention.

Microbicides: What will they do? What will they be like? What needs to be done? Richard A. Cone Johns Hopkins University ReProtect, LLC (“BufferGel™” &

National Working Group on Microbicides The Basics of Microbicides Amitrajit Saha PATH January 2007.

What Is Currently in the Pipeline & What is Ideal for an ARV-based Prevention Candidate? Carl W. Dieffenbach, Ph.D. Director, Division of AIDS, NIAID,

HIV Prevention : Why we need more options for women Wanjiku Kamau Consultant: International AIDS Vaccine Initiative Consultant: International Partnership.

The Microbicide Trials Network Group 3 Lindsay O. Bryant Danielle M. Campbell Alan D. Johnson Leroy Smith Jr. Kendra M. Taylor May 31, 2016.

Partnering to Promote Female-controlled HIV Prevention Methods Matthews J, Becker J, Massey C, Jacobsen J, Patel B Ibis Reproductive Health, International.

Rectal microbicides, where are we? Kim Mulji Naz Foundation International.

Novel Intravaginal Delivery of Antiretroviral-based Microbicides for HIV Prevention HIV/AIDS research Simi Gunaseelan, Ph.D. Assistant Professor of Pharmaceutical.

JOSEPH O’REILLY Deputy Chief Executive REBEKAH WEBB Policy Officer IN COLLABORATION WITH THE GLOBAL CAMPAIGN FOR MICROBICIDES IS THERE AN INVISIBLE CONDOM.

Implications of Anal Intercourse and Rectal use of Products in Vaginal Microbicide Trials Ian McGowan MD PhD FRCP.

$1 Million $500,000 $100,000 $50,000 $25,000 $10,000 $5,000 $1,000.

Microbicides The Population Council Experience and Future Directions Don E. Waldron Medical Director Don E. Waldron Medical Director.

Contraception. Contraception What is contraception? Methods or devices used to prevent pregnancy Methods or devices used to prevent pregnancy.

IAS Members Meeting July 19th 2011 Achievements and learning over the past 30 years: what do we need next? Françoise BARRÉ-SINOUSSI Regulation of Retroviral.

IAS July 1 The Caprisa 004 result in context Sheena McCormack Clinical Scientist MRC Clinical Trials Unit.

Challenges in addressing community understanding of rectal microbicides I am Obiajulu Augustina Amuamuziam and I work for NHVMAS in Lagos, Nigeria. Currently.

New ARV-based prevention tools how the research is happening how we need to be involved Anna Forbes, MSS Consultant, HIV and women’s health HIV Research.

A people-centred perspective Dr Roger Tatoud Imperial College London IRMA Global Teleconference 4 December 2009.

Looking Ahead to MTN-017 Ross D. Cranston MD, FRCP Microbicide Trials Network IRMA.

New Prevention Technologies Workshop Module 2: NPTs in context

$1 Million $500,000 $100,000 $50,000 $25,000 $10,000 $5,000 $1,000.

Contraception. Safe sex versus safer sex The term “Safe sex” is misleading. No sex is the only truly safe sex. Know partner’s sexual history Know partner’s.

CHAIN OF INFECTION STI POINT OF VIEW.

Vaccines and Microbicides Rebekah Webb, AVAC STOPAIDS All Members Meeting: Re-prioritising Prevention London, 12 th May 2016.

Microbicides: New Hope for Prevention of HIV and other STIs Your name here

Information about HIV Prevention Options

Rectal Microbicides: Where We’re Heading

Ian McGowan MD DPhil FRCP University of Pittsburgh Pittsburgh, PA, USA

Sexually transmitted diseases

PrEP Pre-Exposure Prophylaxis

Rectal Gels for PrEP Are They an Option?

Secondary Prevention.

Division of AIDS Office of the Director Workforce Operations,

earching the best evidence

Microbicides: Who, what, where, when and how

Every Mother, Every Child: Closing the Gaps in HIV Management

José Bauermeister PhD, MPH University of Pennsylvania MTN BRWG Member

Rectal Microbicide Protocol Status

Presentation transcript:

Dr Himani

Foams or creams that people can use in vagina or rectum during sex to prevent transmission Currently, there is no vaccine to prevent HIV. This would be the best long-term hope for ending HIV Based on the concept that blocking HIV’s ability to multiply may prevent the infection from taking hold From mother to child and intervention strategies for injection and non- injection drug users MicrobicidesVaccinesPre- exposure Prophylaxis Other areas of research

 Microbicides are gels, films, or suppositories that can kill or neutralize viruses and bacteria.  Researchers are studying both vaginal and rectal microbicides to see if they can prevent sexual transmission of HIV.  A safe, effective, and affordable microbicide against HIV could help to prevent many new infections.

CAPRISA 004 Microbicide Study Researchers put an antiretroviral drug into vaginal microbicide gel and told participants in trial to use the gel before and after sex to protect against HIV transmission Gel was 39% effective in reducing women’s risk of becoming infected with HIV during sex Gel was 51% effective in preventing genital herpes infection

 1987 : 1 st vaccine clinical trial opened  1992 : 1 st phase II HIV clinical trial  1999: AIDSVAX in Thailand  2003: RV 144 initiated, phase 3 trial

 Preventive vaccine  Therapeutic vaccine

Vaccine trial Candidate vaccine(s)PhaseResult VAX 003Protein:rgp120IIINo efficacy VAX 004Protein:rgp120IIINo efficacy RV144Pox/protein: ALVAC/rgp120 III31% efficacy HVTN 502/ Merck 023 Adenovirus type 5 (Ad5) gag/pol/nef IIbNo efficacy HVTN503Ad5 gag/pol/nefIIbNo efficacy HVTN505DNA-Ad5 gag/pol/nef/env IIbNo efficacy

Vaccine trialPhaseResult RemuneIIINo efficacy EraMune02IOngoing Vacc-4x--

Thanks